AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01093183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given PO
Study NCT01093183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04017702 — intervention group
Intervention type: DEVICE
Intervention: Expiron respirator
Description: Respiratory volume monitor (RVM) (ExSpiron, is a non-invasive FDA approved device that monitors minute ventilation (MV) and provides an early indication of respiratory status in non-intubated patients. The system consists of a lightweight monitor, a patient cable, and a disposable electrode PadSet, which detects changes in breathing.
Study NCT03710070 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: Angiography of the IMA without occlusion
Study NCT00504491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab-CHOP-Alemtuzumab
Description: Four Rituximab - CHOP courses will be given The courses will be given every 21 days
Study NCT01585324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg subcutaneously weekly
Study NCT01585324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1000 mg or 1200 mg orally daily
Study NCT01032421 — intervention group
Intervention type: PROCEDURE
Intervention: IVF procedure
Study NCT01481584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink - protein isolate
Description: The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein isolate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
Study NCT01481584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein drink - protein isolate
Description: The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein isolate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
Study NCT01481584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein drink - protein hydrolyzate
Description: The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein hydrolyzate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
Study NCT01481584 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein drink - protein hydrolyzate
Description: The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein hydrolyzate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
Study NCT02378415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IV Bolus dose of ketamine dosed at 0.2mg/kg infused over 1-2 minutes.
Study NCT02378415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline Infusion
Study NCT04855617 — intervention group
Intervention type: DRUG
Intervention: Ocrelizumab
Description: Administer Ocrelizumab under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions such as serious infusion reactions.~* Initial dose: 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion.~* Subsequent doses: single 600 mg intravenous infusion every 6 months.~* Observe the patient for at least one hour after the completion of the infusion
Study NCT02987517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increased running cadence gait retraining
Description: Runners use an increased cadence, or step rate, 7.5% greater than baseline preferred cadence
Study NCT02987517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forefoot Strike gait retraining
Description: Runners use a forefoot strike running gait instead of a rear foot strike running gait.
Study NCT02987517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening exercises
Description: foot and ankle strengthening exercises performed by all subjects to prepare musculoskeletal tissues for requirements of new running gait.
Study NCT01701297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cotrimoxazole
Description: Cotrimoxazole 960mg orally each day (two 480mg tablets)
Study NCT01701297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSL#3 active
Description: The prescribed dose was 2 sachets (containing 900 billion bacteria) orally each day for 48 weeks
Study NCT01701297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VSL#3 placebo
Description: This was two placebo sachets identical to VSL#3 active sachet. The prescribed dose was 2 sachets orally each day for 48 weeks
Study NCT00005072 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leuvectin
Description: 1000 ug of Leuvectin injected intratumorally
Study NCT02983435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: G1 - Thrust manipulation
Description: Osteopathic manipulation with Thrust technique. The Group 1 (G1) will receive the Thrust technique applied at the level of dysfunction. Subject in lateral decubitus, with one lower limb extended and the other in flexion, to the level of the targeted vertebra; upper trunk rotated back until the same vertebra; at the end of the range of movement will be applied the high speed and low amplitude impulse (Thrust).
Study NCT02983435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: G2 - Muscle Energy
Description: Osteopathic manipulation with Muscle Energy technique. The Group 2 (G2) will receive the Muscle Energy technique applied at the level of dysfunction. Subject in lateral decubitus, with the upper and lower trunk flexed until the target vertebra, and upper trunk rotated back to the level of the same vertebra; lumbar in lateral flexion (using the subject's feet) until the target vertebra. Following the command the subject will perform an isometric contraction of 3-5 seconds against the therapist's hand (pushing the hand towards the floor), repeated 3 times.
Study NCT02691728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF FDC
Study NCT01690910 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rifton Gait Trainer
Study NCT01690910 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Front Wheeled Walker
Study NCT04399408 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Obstetrics Ultrasound (non invasive)
Description: Participants are instructed to preform 1-3 short (3 minuets) ultrasound scans a day according to pre-defined steps.
Study NCT01524783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Participants were treated with everolimus 10 mg (two 5 mg tablets) once daily orally taken
Study NCT01524783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were treated with two tablets of matching placebo once daily orally taken.
Study NCT01524783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best suportive care (BSC)
Description: Best supportive care includes all care provided to participants deemed necessary by the treating physician, such as but not restricted to anti-diarrheals and analgesics. The optimal care of the patient is based on the treating physician's best medical judgment.
Study NCT01524783 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best suportive care (BSC)
Description: Best supportive care includes all care provided to participants deemed necessary by the treating physician, such as but not restricted to anti-diarrheals and analgesics. The optimal care of the patient is based on the treating physician's best medical judgment.
Study NCT02333721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy including No. 10
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
Study NCT02333721 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: D2 lymphadenectomy excluding No. 10
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
Study NCT01632904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be orally self-administered at a starting dose of 10 mg (two 5 mg tablets) twice a day. Dose increases of 5 mg (1 tablet) in twice-daily increments are permitted after 4 weeks and again after 8 weeks of therapy for subjects who meet prespecified criteria for inadequate efficacy.
Study NCT01632904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea (HU)
Description: Hydroxyurea (500 mg capsules) will be orally self-administered at the dose that the subject was receiving previously. The dose may be increased after 4 weeks and again after 8 weeks of therapy to optimize efficacy for subjects meeting prespecified criteria.
Study NCT01632904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HU-placebo
Description: All placebo will be self-administered, and dosing will be the same as with the blinded dose.~When adjustments are made to the ruxolitinib dose, the dose of HU-placebo will be adjusted concurrently.
Study NCT01632904 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib-placebo
Description: All placebo will be self-administered, and dosing will be the same as with the blinded dose.~When adjustments are made to the HU dose, the dose of ruxolitinib-placebo will be adjusted concurrently.
Study NCT04457375 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: TDC
Description: measurements
Study NCT01552915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate
Description: Daily oral dosing in the AM of optimized dose, ranging from 30- 70 mg. 5 week dose optimization, 3 week dose maintenance
Study NCT01552915 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate Hydrochloride
Description: Daily oral dosing in the AM of optimized dose, ranging from 18-72 mg. 5 week dose optimization, 3 week dose maintenance
Study NCT01552915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dosing in the AM for 8 weeks
Study NCT03547362 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein
Description: See arm description
Study NCT03547362 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy protein blend 1
Description: See arm description
Study NCT03547362 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: See arm description
Study NCT03547362 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy protein blend 2
Description: See arm description
Study NCT03547362 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy protein blend 3
Description: See arm description
Study NCT03547362 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dairy protein blend 4
Description: See arm description
Study NCT01546168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: esophageal deviation with IDE device
Description: esophageal deviation during AF ablation
Study NCT03978247 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NASHMIR
Description: An additional blood sample will be taken upstream of the surgical procedure and a liver biopsy will be performed in all included patients. The two results obtained by the spectroscopic test and by means of the biopsy will then be compared to determine the diagnostic performance of the developped test (NASHMIR test).
Study NCT00175032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole and naproxen and aspirin
Description: Lansoprazole 30 mg, capsules, orally once daily; Naproxen 500 mg, capsules, orally, twice daily; and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT00175032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib and aspirin
Description: Celecoxib 200 mg, capsules, orally once daily and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT01756105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of
Study NCT01756105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid acting analog insulin Intermediate acting NPH Insulin
Description: Insulin therapy:If post meal (2 hours after meal) glycaemia is > to 120 mg/dl introduce Insulin rapid acting analog (Humalog\*, Novorapid\*) before the meal concerned and according to the weight. If weight is \< 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is > 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH\*, insulatard\*) before sleeping : 5U if weight is \< 80 kg - 6U if weight is > 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
Study NCT01756105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapid acting analog insulin Intermediate acting NPH Insulin
Description: Insulin therapy:If post meal (2 hours after meal) glycaemia is > to 120 mg/dl introduce Insulin rapid acting analog (Humalog\*, Novorapid\*) before the meal concerned and according to the weight. If weight is \< 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is > 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH\*, insulatard\*) before sleeping : 5U if weight is \< 80 kg - 6U if weight is > 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
Study NCT03480698 — intervention group
Intervention type: DRUG
Intervention: Cerebrolysin
Description: Dosage, frequency, duration and mode of administration of Cerebrolysin follow the local hospital practice in accordance with the terms of the local marketing authorization and is not amended or influenced by the study. Prescribed Cerebrolysin will be used as solution for injection/concentrate for solution for infusion.
Study NCT00962091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib OS Alisertib PIC Alisertib PIC
Study NCT03491631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR9146+SHR-1210
Description: SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W
Study NCT03491631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR9146+SHR-1210+Apatinib
Description: SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W Apatinib:250mg QD
Study NCT02034396 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood Draw
Description: One blood draw at enrollment
Study NCT01001598 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: danazol
Description: Dosage is done according to weight; capsules are 50, 100, 200 mg
Study NCT00711828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV
Study NCT00711828 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT00711828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO
Study NCT00711828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT00711828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
Study NCT00711828 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
Study NCT01759316 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: heliox
Description: heliox or oxygen is used in the two groups respectively
Study NCT01759316 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: heliox
Description: heliox or oxygen is used in the two groups respectively
Study NCT02253771 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shockwave therapy
Description: Shockwave therapy with 2000 impulses/treatment at 12 Hz; 8 treatment over 4 weeks, twice a week
Study NCT02253771 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo shockwave therapy
Description: sham shockwave therapy by an identically looking device without any function
Study NCT03243344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgiflo
Description: using device during the endonasal surgery.
Study NCT03243344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Floseal
Description: using device during the endonasal surgery.
Study NCT03243344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algosteril
Description: using device during the endonasal surgery.
Study NCT01979471 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Advanced Care
Description: The pharmacist will complete a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA), which will include:~* Patient assessment~* Laboratory assessment of HbA1c and lipids~* Individual assessment of CVD risk and education about this risk~  * Calculation of cardiovascular risk will be facilitated by an online tool~ * Discussion of CVD risk with the patient using the interactive online tool which explains his/her individual cardiovascular risk and targets for intervention and providing the patient with education on cardiovascular risk factors and healthy lifestyle options~* Treatment recommendations, Prescription adaptation(s), and/or prescribe where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation.~* Regular communication with the patient's family physician after each contact with the patient~* Regular follow-up with all patients a minimum of every 3-4 weeks for 3 months.
Study NCT00150124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTZ+LT4
Study NCT00150124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methimazole
Study NCT01772849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors Continued individualized education at the hospital school or at home that parallels/copies the educational curriculum in the child regular school At two weks intervals joined education, physical (separate study) and social activity days at the hospital with together with one of the ambassadors
Study NCT02056106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antidepressant therapy
Study NCT01070836 — intervention group
Intervention type: DRUG
Intervention: natalizumab
Description: Administered as specified in the treatment arm
Study NCT02416648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Client Centered (CCC) Counseling
Description: Counseling sessions were interactive allowing for listening, questions and answers. They were cultural sensitive and also consider issues related to gender and age. Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.~Clinicians evaluated patients' readiness to change risky or maintain safer behaviors. They also assisted the patient to negotiate an individually tailored behavior change or maintenance plan of action.
Study NCT01881880 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bilateral mammography with Tomosynthesis
Description: no intervention pre specified to be administered to participants
Study NCT02294175 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Larval Debridement Therapy
Description: small sterile mesh bags containing live maggots placed into an open chronic wound to remove necrotic tissue and bacterial biofilm